Recently, the society of Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology announced that Human Papilloma Virus (HPV) test is extremely effective to identify cervical cancer.

The health organizations also confirm that this screening can replace the present US cytology based cervical cancer test. The guidance report merely considered it as primary HPV test and explained its advantages and side effects. Additionally, it recommends that basic HPV screening should begin from the age of 25. However, women who are younger than the given age should go for current Pap test only.

The two most prominent women’s health organizations received FDA approval for   the cobas HPV test. The government health agency officially permitted it as a basic test for cervical cancer screening.

On the other hand, the American College of Obstetricians & Gynecologists (ACOG) is completely against the new test.  The biggest ob-gyn group of the United States believes that women should still get Pap test alone. However, they can take this new test with a combination: HPV test and Pap test.

Warner K. Huh MD, a researcher at University of Alabama informs that HPV screening is extremely sensitive. It relies on subsequent assessment strategies and regular screening.  The approval of US Food and Drug Administration does not contain recommendation to implement the new screening in the Untied States.

The study is printed in detail on 7th January’s edition of Journal Gynecologic Oncology.